Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.
Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.
Hims & Hers (HIMS) Sees 69% Revenue Increase Despite GLP-1 Uncertainties
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration ...
Hims & Hers shares tumble as margin miss adds to concerns about GLP-1 business
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...
The GLP-1 Revolution — How Private Equity Investors Are Capitalizing
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Fierce Healthcare4d
Hims & Hers projects weight loss business to hit $725M in 2025 despite GLP-1 market shift
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
KIVI-TV3d
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Modern Healthcare1d
GLP-1 compounding pharmacies sue FDA over shortage decision
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
Fierce Healthcare7d
FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market, for now
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
KERO-TV4d
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
Hims has sold one-month doses of GLP-1 semaglutides starting at $165 per month. The list cost of Wegovy is $1,349, and one dose is generally taken every four weeks. Andrew Dudum, co-founder of ...